Rohto Pharmaceutical and Mitsui & Co. announce acquisition of Chinese herbal medicine manufacturer in Singapore.
The acquisition price is said to be approximately 88 billion yen in Japanese yen. Rohto Pharmaceutical aims to strengthen its business in the health field, including disease prevention, by combining the acquired company's brand power in Asia with its own R&D strengths. Chairman Kunio Yamada said at a press conference, ``As the population continues to age in Asia, prevention will become more important than ever.''